Download Ibuprofen Bril 200 mg Film

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Ibuprofen Bril 200 mg film-coated tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 200 mg ibuprofen
Excipient with known effect: lactose monohydrate 8mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Film-coated tablets
Ibuprofen Bril 200 mg film-coated tablets are white, about 9.5 mm circular, film coated
tablets, plain on both the sides.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
For short term symptomatic treatment of mild to moderate pain such as headache
(including migraine), dysmenorrhea (period pain), dental pain, and fever and pain in
common cold.
4.2 Posology and method of administration
For oral use.
Undesirable effects may be minimised by using lowest effective dose for the shortest duration
necessary to control symptoms (see section 4.4)
The tablet should be swallowed with a glass of water during or after meal
The ibuprofen dose depends on the patient’s age and body weight.
Mild to moderate pain and fever
Adults and adolescents older than 12 years (≥40 kg):
200-400 mg given as a single dose or 3 times a day with an interval of 4 to 6 hours.
The dosage in migraine headache should be: 400 mg given as a single dose, if necessary 400 mg
with intervals of 4 to 6 hours. The maximum daily dose should not exceed 1200 mg.
If in adults this product is required for more than 3 days in the case of fever or migraine headache,
or for more than 4 days for pain relief, or if symptoms worsen the patient is advised to consult a
doctor.
If in children and adolescents, this medicinal product is required for more than 3 days, or if
symptoms worsen a doctor should be consulted.
Children 6-12 years (>20 kg)
Children 6-9 years (20-29 kg):
200 mg 1-3 times a day with intervals of 4 to 6 hours as required. The maximum daily dose
should not exceed 600 mg.
Children 10-12 years (30-40 kg):
200 mg 1-4 times a day with intervals of 4 to 6 hours as required. The maximum daily dose
should not exceed 800 mg.
Primary dysmenorrhoea
Adults and adolescents older than 12 years (≥40 kg):
1-2 tablets to be taken 1-3 times a day, with an interval of 4-6 hours. The maximum daily dose
should not be more than 6 tablets (1200mg)
Special populations:
Paediatric population:
If in children aged from 6 years and in adolescents this medicinal product is required for more
than 3 days, or if symptoms worsen a doctor should be consulted.
Ibuprofen Bril 200 mg film-coated tablets is contraindicated in children younger than 6 years of
age (below 20 kg body weight) due to the large amount of active substance.
Older people
NSAIDs should be used with particular caution in elderly patients who are more prone to adverse
events and are at increased risk of potentially fatal gastrointestinal haemorrhage, ulceration or
perforation (see section 4.4). If treatment is considered necessary, the lowest dose for the shortest
duration necessary to control symptoms should be used. Treatment should be reviewed at regular
intervals and discontinued if no benefit is seen or intolerance occurs.
Impaired renal function
In patients with mild or moderate reduction of renal function, the dose should be kept as low as
possible for the shortest duration necessary to control symptoms and renal function monitored.
(For patients with severe renal failure see section 4.3).
Impaired liver function
In patients with mild or moderate reduction of liver function the dose should be kept as low as
possible for the shortest duration necessary to control symptoms and liver function monitored.
(For patients with severe liver failure see section 4.3).
4.3 Contraindications
Ibuprofen Bril Tablets is contraindicated in patients with:
-
hypersensitivity to the active substance or to any of the excipients listed in 6.1
previous hypersensitivity reactions (e.g. asthma, rhinitis, urticaria or angioedema) in
response to acetylsalicylic acid or other NSAIDs
history of gastrointestinal bleeding or perforation, related to previous NSAIDs
therapy
active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct
episodes of proven ulceration or bleeding)
severe hepatic or severe renal insufficiency
severe heart failure (NYHA Class IV)
last trimester of pregnancy (see section 4.6)
significant dehydration (caused by vomiting, diarrhoea or insufficient fluid intake)
cerebrovascular or other active bleeding
dishaematopoiesis of unknown origin
children younger than 6 years of age (below 20 kg body weight) because this tablet
strength is not suitable due to the large amount of active substance.
4.4 Special warnings and precautions for use
The use of Ibuprofen Bril Tablets with concomitant NSAIDs including cyclooxygenase-2
selective inhibitors should be avoided.
Undesirable effects may be minimised by using the lowest effective dose for the shortest
duration necessary to control symptoms (see section 4.2 and GI and cardiovascular risks
below). Patients treated with NSAIDs long term should undergo regular medical
supervision to monitor for adverse events.
Ibuprofen Bril Tablets should only be administered under strict consideration of the
benefit-risk ratio in the following conditions:
-
Systemic Lupus Erythematosus (SLE) or other autoimmune diseases.
Congenital disturbance of porphyrin metabolism (e.g. acute intermittent porphyria)
The first and second trimester of pregnancy
Lactation
Special care has to be taken in the following cases:
-
Gastrointestinal diseases including chronic inflammatory intestinal disease (ulcerative
colitis, Crohn's disease)
Cardiac insufficiency and hypertension
Reduced renal function
Hepatic dysfunction
Disturbed haematopoiesis
Blood coagulation defects
-
Allergies, hay fever, chronic swelling of nasal mucosa, adenoids, chronic obstructive
airway disease or bronchial asthma
Immediately after major surgical interventions
Gastrointestinal bleeding, ulceration and perforation
GI bleeding, ulceration or perforation, which can be fatal, has been reported with all
NSAIDs at any time during treatment, with or without warning symptoms or a previous
history of serious GI events.
The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses,
in patients with a history of ulcer, particularly if complicated with haemorrhage or
perforation (see section 4.3), and in the elderly. These patients should commence
treatment on the lowest dose available.
Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors)
should be considered for these patients, and also for patients requiring concomitant lowdose acetylsalicylic acid, or other medicinal products likely to increase gastrointestinal
risk. (See below and section 4.5).
Patients with a history of GI toxicity, particularly when elderly, should report any
unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of
treatment.
Caution should be advised in patients receiving concomitant medications which could
increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants
such as warfarin or heparin, selective serotonin-reuptake inhibitors or anti-platelet agents
such as acetylsalicylic acid (see section 4.5).
When GI bleeding or ulceration occurs in patients receiving Ibuprofen Bril Tablets, the
treatment should be withdrawn.
NSAIDs should be given with care to patients with a history of gastrointestinal disease
(ulcerative colitis, Crohn’s disease) as their condition may be exacerbated. (See section
4.8).
Older people
The older people have an increased frequency of adverse reactions to NSAIDs, especially
gastrointestinal bleeding and perforation which may be fatal (see section 4.2).
Cardiovascular and cerebrovascular effects
Appropriate monitoring and advice are required for patients with a history of
hypertension and/or mild to moderate congestive heart failure as fluid retention,
hypertension and oedema have been reported in association with NSAID therapy.
Clinical studies suggest that use of ibuprofen, particularly at high dose (2400 mg/day),
may be associated with a small increased risk of arterial thrombotic events (for example
myocardial infarction or stroke). Overall, epidemiological studies do not suggest that lowdose ibuprofen (e.g. ≤ 1200 mg/day) is associated with an increased risk of arterial
thrombotic events..
Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III),
established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular
disease should only be treated with ibuprofen after careful consideration and high doses
(2400 mg/day) should be avoided. Similar consideration should be made before initiating
longer-term treatment of patients with risk factors for cardiovascular events (e.g.
hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses of
ibuprofen (2400 mg/day) are required.
Skin reactions
Serious skin reactions, some of them fatal, including exfoliative dermatitis, StevensJohnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in
association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk
of these reactions early in the course of therapy, the onset of the reaction occurring in the
majority of cases within the first month of treatment. Ibuprofen Bril Tablets should be
discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of
hypersensitivity.
Renal effect
Ibuprofen may cause the retention of sodium, potassium and fluid in patients who have
not previously suffered from renal disorders because of its effect on renal perfusion. This
may cause oedema or even lead to cardiac insufficiency or hypertension in predisposed
patients.
As with other NSAIDs, the prolonged administration of ibuprofen to animals has resulted
in renal papillary necrosis and other pathological renal changes. In humans, there have
been reports of acute interstitial nephritis with haematuria, proteinuria and occasionally
nephrotic syndrome. Cases of renal toxicity have also been observed in patients in whom
prostaglandins play a compensatory role in the maintenance of renal perfusion. In these
patients, administration of NSAIDs may cause a dose-dependent reduction in
prostaglandin formation and, secondarily, in renal blood flow, which may precipitate
overt renal decompensation. Patients at greatest risk of suffering this reaction are those
with renal dysfunction, heart failure, hepatic dysfunction, those taking diuretics and ACE
inhibitors and the elderly. Discontinuation of NSAID treatment is generally followed by
recovery to the pre-treatment state.
There is a risk of renal impairment in dehydrated children and adolescents.
Other precautions
Bronchospasm, urticaria or angioedema may be precipitated in patients suffering from or
with a previous history of bronchial asthma, chronic rhinitis, sinusitis, nasal polyps,
adenoids or allergic diseases.
Ibuprofen may mask the signs or symptoms of an infection (fever, pain and swelling).
Prolonged use of any type of painkiller for headaches can make them worse. If this
situation is experienced or suspected, medical advice should be obtained and treatment
should be discontinued. The diagnosis of medication overuse headache (MOH) should be
suspected in patients who have frequent or daily headaches despite (or because of) the
regular use of headache medications. In general the habitual intake of analgesics,
particularly the combination use of different analgesic substances, may cause permanent
renal damage and a risk of renal failure (analgesics nephropathy).
During treatment with ibuprofen, some cases with symptoms of aseptic meningitis, such
as stiff neck, headache, nausea, vomiting, fever or disorientation have been observed in
patients with existing auto-immune disorders (such as systemic lupus erythematosus,
mixed connective tissue disease).
Ibuprofen may temporarily inhibit platelet aggregation and prolong the bleeding time.
Therefore, patients with coagulation defects or on anticoagulant therapy should be
observed carefully.
In case of long-term treatment with ibuprofen a periodical monitoring of hepatic and renal
function as well as the blood count is necessary, especially in high risk patients.
Consumption of alcohol should be avoided since it may intensify side effects of NSAIDs,
especially if affecting the gastrointestinal tract or the central nervous system.
Patients on ibuprofen should report to their doctor signs or symptoms of gastro-intestinal
ulceration or bleeding, blurred vision or other eye symptoms, skin rash, weight gain or
oedema.
There is some evidence that medicinal products which inhibit cyclo-oxygenase/
prostaglandine synthesis may cause impairment of female fertility by an effect on
ovulation. This is reversible on withdrawal of treatment.
Patients with rare hereditary problem of galactose intolerance, the Lapp lactase deficiency
or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Concomitant use of ibuprofen and the following substances should be avoided:
Acetylsalicylic acid: Concomitant administration of ibuprofen and acetylsalicylic acid is
not generally recommended because of the potential of increased adverse effects.
Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose
acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Although
there are uncertainties regarding extrapolation of these data to the clinical situation, the
possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect
of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is
considered to be likely for occasional ibuprofen use (see section 5.1)
Other NSAIDs: As a result of synergistic effects, the concurrent use of several NSAIDs
can increase the risk of gastrointestinal ulcers and haemorrhage. Co-administration of
ibuprofen with other NSAIDs should therefore be avoided (see section 4.4).
Anti-coagulants: NSAIDs may enhance the effects of anticoagulants, such as warfarin or
heparin (see section 4.4). In case of simultaneous treatment, monitoring of the
coagulation state is recommended.
Ticlopidin: NSAIDs should not be combined with ticlopidine due to a risk of an additive
effect in the inhibition of the platelet function.
Methotrexate: NSAID inhibits the tubular secretion of methotrexate and certain metabolic
interactions can occur resulting in decreased clearance of methotrexate. The
administration of Ibuprofen Bril Tablets within 24 hours before or after the administration
of methotrexate can lead to an elevated concentration of methotrexate and an increase in
its toxic effects. Therefore, concomitant use of NSAIDs and high doses of methotrexate
should be avoided. Also, the potential risk of interactions in low dose treatment with
methotrexate should be considered, especially in patients with impaired renal function. In
combined treatment, renal function should be monitored.
Ibuprofen (like other NSAIDs) should be taken only with caution in combination with the
following substances:
Moclobemide: Enhances the effect of ibuprofen.
Phenytoin, lithium and digoxin: The concomitant use of ibuprofen with digoxin,
phenytoin or lithium preparations may increase serum levels of these medicinal products.
A check of serum-lithoum, serum digoxin and serum-phenytoin is not as a rule required
on correct use (maximum over 4 days).
Diurectis and antihypertensives: Diuretics and ACE-inhibitors can increase the
nephrotoxicity of NSAIDs. NSAIDs can reduce the effect of diuretics and
antihypertensives including ACE-inhibitors and beta-blockers. In patients with reduced
kidney function (e.g. dehydrated patients or elderly patients with reduced kidney
function), the concomitant use of an ACE inhibitor and angiotension II antagonist with a
cyclooxygenase-inhibiting medicinal product can lead to further impairment of kidney
function and through to acute renal failure. This is usually reversible. Such combination
should therefore only be used with caution, especially in elderly patients. The patients
have to be instructed to drink sufficient liquid and periodic monitoring of the kidney
values should be considered for the time immediately after the start of the combination
therapy.
The concomitant administration of Ibuprofen Bril and potassium sparing diuretics or ACE
inhibitors can result in hyperkalaemia.
Captopril: Experimental studies indicate that ibuprofen counteracts the effect of captopril
of increased sodium excretion.
Aminoglycosides: NSAIDs can slow down the elimination of aminoglycosides and
increase their toxicity.
Selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding
(see section 4.4).
Ciclosporine: The risk of kidney damage by ciclosporin is increased by the concomitant
administration of certain NSAIDs. This effect cannot be ruled out for the combination of
ciclosporine and ibuprofen, either.
Cholestyramine: Concomitant treatment with cholestyramine and ibuprofen results in
prolonged and reduced (25%) absorption of ibuprofen. The medicinal products should be
administered with at least one hour interval.
Tacrolimus: Elevated risk of nephrotoxicity.
Zidovudine: There is evidence of an increased risk of haemarthrosis and haematoma in
HIV positive haemophilia patients receiving concurrent treatment with zidovudine and
ibuprofen. There may be an increased risk of haematotoxicity during concomitant use of
zidovudine and NSAIDs. Blood counts 1-2 weeks after starting use together are
recommended.
Ritonavir: May increase the plasma concentrations of NSAIDs.
Mifepristone: If NSAIDs are used within 8-12 days after mifepristone administration they
can reduce the effect of mifepristone.
Probenecid or sulfinpyrazone: May cause a delay in the elimination of ibuprofen. The
uricosuric action of these substances is decreased.
Quinolone antibiotics: Patients taking NSAIDs and quinolones may have an increased
risk of developing convulsions.
Sulphonylureas: NSAIDs can increase the hypoglycemic effect of sulphonylureas. In the
case of simultaneous treatment, monitoring of blood glucose levels is recommended.
Corticosteroids: Increased risk of gastrointestinal ulceration or bleeding (see section 4.4).
Anti-platelet aggregation agents (e.g. clopidogrel and ticlopidine): Increase the risk of
gastrointestinal bleeding (see section 4.4).
Alcohol, bisphosphonates and oxpentifylline (pentoxyflline): May potentiate the GI sideeffects and the risk of bleeding and ulceration.
Baclofen: Elevated baclofen toxicity.
CYP2C9 Inhibitors: Concomitant administration of ibuprofen with CYP2C9 inhibitors
may increase the exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole
and fluconazole (CYP2C9 inhibitors) an increased S(+)-ibuprofen exposure by
approximately 80 to 100% has been shown. Reduction of the ibuprofen dose should be
considered when potent CYP2C9 inhibitors are administered concomitantly, particularly
when high-dose ibuprofen is administered with either voriconazole or fluconazole.
4.6 Fertility, pregnancy and lactation
Pregnancy
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the
embryo/foetal development. Data from epidemiological studies suggest an increased risk
of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin
synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation
was increased from less than 1%, up to approximately 1.5%. The risk is believed to
increase with dose and duration of therapy. In animals, administration of a prostaglandin
synthesis inhibitor has been shown to result in increased pre- and post- implantation loss
and embryo-foetal lethality. In addition, increased incidences of various malformations,
including cardiovascular, have been reported in animals given a prostaglandin synthesis
inhibitor during the organogenetic period. During the first and second trimester of
pregnancy, Ibuprofen Bril Tablets should not be given unless clearly necessary. If
Ibuprofen Bril Tablets is used by a woman attempting to conceive, or during the first and
second trimester of pregnancy, the dose should be kept as low and duration of treatment
as short as possible.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose
the foetus to:
-
cardiopulmonary toxicity (with premature closure of the ductus arteriosus and
pulmonary hypertension);
renal dysfunction, which may progress to renal failure with oligo-hydramniosis;
The mother and the neonate, at the end of pregnancy to:
-
possible prolongation of bleeding time, an anti-aggregating effect which may occur
even at very low doses.
-
inhibition of uterine contractions resulting in delayed or prolonged labour.
Consequently Ibuprofen Bril Tablets is contraindicated during the last trimester of
pregnancy.
Breast-feeding
Ibuprofen is excreted in breast milk, but with therapeutic doses during short term
treatment, the risk for influence on infant seems unlikely. If, however, longer treatment is
prescribed, early weaning should be considered.
Fertility
The use of ibuprofen may impair fertility and is not recommended in women attempting
to conceive. In women who have difficulties conceiving or who are undergoing
investigation of infertility, withdrawal of ibuprofen should be considered.
4.7 Effects on ability to drive and use machines
Ibuprofen generally has no adverse effects on the ability to drive and use machinery.
However since at high dosage side effects such as fatigue, somnolence, vertigo (reported
as common) and visual disturbances (reported as uncommon) may be experienced, the
ability to drive a car or operate machinery may be impaired in individual cases. This
effect is potentiated by simultaneous consumption of alcohol.
4.8 Undesirable effects
The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers,
perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see
section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal
pain, melaena, heamatemesis, ulcerative stomatitis, exacerbation of colitis and Crohn’s
disease (see section 4.4) have been reported following administration. Less frequently,
gastritis has been observed.
Undesirable effects are mostly dose-dependent. Especially the risk for the occurrence of
gastrointestinal bleedings depends on the dosage range and duration of the treatment.
Other known risk factors, see section 4.4.
Clinical studies suggest that use of ibuprofen, particularly at high dose (2400 mg/day)
may be associated with a small increased risk of arterial thrombotic events (for example
myocardial infarction or stroke) (see section 4.4).
Oedema, hypertension, and cardiac failure, have been reported in association with NSAID
treatment.
The undesirable effects are less frequent when the maximum daily dose is 1200 mg.
Assessment of adverse reactions is normally based on the following occurrence
frequency:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Body System
Undesirable Effect
Frequency
Investigations
increase of blood urea nitrogen, serum Rare
transaminases and alkaline phosphatase,
decrease
in
haemoglobin
and
haematocrit values, inhibition of platelet
aggregation, prolonged bleeding time,
decrease of serum calcium, increase in
serum uric acid
Cardiac disorders
palpitations, heart failure, myocardial Very rare
infarction, acute pulmonary oedema,
oedema
Blood and lymphatic system haematopoietic disorders (anaemia, Very rare
disorders
leucopoenia,
thrombocytopenia,
pancytopenia, agranulocytosis). The first
symptoms or signs may include: fever,
sore throat, surface mouth ulcers, flulike symptoms, severe fatigue, nasal and
skin bleeding
Nervous System disorders
Eye disorders
Ear and labyrinth disorders
headache, somnolence, vertigo, fatigue, Common
agitation, dizziness, insomnia, irritability
aseptic meningitis
Very rare
visual disturbances
Uncommon
toxic amblyopia
Rare
Tinnitus
Very rare
Respiratory, thoracic and rhinitis, bronchospasm
mediastinal disorders
Uncommon
Gastrointestinal disorders
Very common
Gastrointestinal disorders such as
heartburn, dyspepsia, abdominal pain
and nausea, vomiting, flatulence,
diarrhoea, constipation
gastrointestinal ulcers, sometimes with Common
bleeding and perforation (see section
4.4), occult blood loss which may lead
to anaemia, melaena, haematemesis,
ulcerative
stomatitis,
colitis,
exacerbation of inflammatory bowel
disease, complications of colonic
diverticula (perforation, fistula)
Renal and urinary disorders
Gastritis
Uncommon
oesophagitis, pancreatitis, intestinal
strictures.
Very rare
development of oedema especially in Uncommon
patients with arterial hypertension or
renal insufficiency, nephrotic syndrome,
interstitial nephritis which can be
associated with renal failure
renal papillary necrosis in long-term use Very rare
(see section 4.4)
Skin and subcutaneous photosensitivity
Uncommon
tissue disorders
severe forms of skin reactions (erythema Very rare
multiforme,
exfoliative
dermatitis,
bullous reactions including StevensJohnson syndrome and toxic epidermal
necrolysis, alopecia, necrotising fascitis
Vascular disorder
hypertension
Very rare
Immune System disorders
hypersensitivity reactions such as Uncommon
urticaria,
pruritus,
purpura
and
exanthema as well as asthma attacks
(sometimes with hypotension)
Lupus erythematosus syndrome
Rare
severe hypersensitivity reactions. The Very rare
symptoms may include: facial oedema,
swelling of the tongue, internal laryngeal
swelling with constriction of the airways,
dyspnoea, tachycardia, fall of blood
pressure to the point of life-threatening
shock.
Hepatobiliary disorders
Psychiatric disorder
liver dysfunction, liver damage,
especially in long-term use, liver failure,
acute hepatitis, jaundice
Very rare
depression, confusion, hallucinations
Rare
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions via
the national reporting system
(To be completed nationally)
4.9 Overdose
Symptoms
Most patients who have ingested clinically important amounts of NSAIDs will develop no
more than nausea, vomiting, epigastric pain, or more rarely, diarrhoea. Tinnitus,
headache, dizziness, vertigo and gastrointestinal bleeding may also occur. In more serious
poisoning, toxicity is seen in the central nervous system, manifesting as drowsiness,
occasionally excitation and disorientation or coma. Occasionally patients develop
convulsions. Children may also develop myoclonic cramps. In serious poisoning
metabolic acidosis may occur and the prothrombin time/INR may be prolonged, probably
due to the actions of circulating clotting factors. Acute renal failure, liver damage,
hypotension, respiratory depression and cyanosis may occur. Exacerbation of asthma is
possible in asthmatics.
Treatment
Treatment should be symptomatic and supportive and include the maintenance of a clear
airway and monitoring of cardiac and vital signs until stable. Gastric emptying or oral
administration of activated charcoal is indicated if the patient presents within one hour of
ingestion of more than 400 mg per kg of body weight. If Ibuprofen Bril Tablets has
already been absorbed, alkaline substances should be administered to promote the
excretion of the acid ibuprofen in the urine. If frequent or prolonged, convulsions should
be treated with intravenous diazepam or lorazepam. Bronchodilators should be given for
asthma. No specific antidote is available.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids;
propionic acid derivatives. ATC code: M01AE01
Ibuprofen is a NSAID that possesses anti-inflammatory, analgesic and antipyretic
activity. Animal models for pain and inflammation indicate that ibuprofen effectively
inhibits the synthesis of prostaglandins. In humans, ibuprofen reduces pain possibly
caused by inflammation or connected with it, swelling and fever. Ibuprofen exerts an
inhibitory effect on prostaglandin synthesis by inhibiting the activity of cyclo-oxygenase.
In addition ibuprofen has an inhibitory effect on ADP (adenosine diphosphate) or
collagen-stimulated platelet aggregation.
Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose
acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Some
pharmacodynamic studies show that when single doses of ibuprofen 400 mg were taken
within 8 h before or within 30 min after immediate release acetylsalicylic acid dosing (81
mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet
aggregation occurred. Although there are uncertainties regarding extrapolation of these
data to the clinical situation, the possibility that regular, long-term use of ibuprofen may
reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No
clinically relevant effect is considered to be likely for occasional ibuprofen use (see
section 4.5). Ibuprofen inhibits prostaglandin synthesis in the uterus, thereby reducing
intrauterine rest and active pressure, the periodic uterine contractions and the amount of
prostaglandins released into the circulation. These changes are assumed to explain the
alleviation of menstrual pain. Ibuprofen inhibits renal prostaglandin synthesis which can
lead to renal insufficiency, fluid retention and heart failure in risk patients (see section
4.3).
Prostaglandins are connected with ovulation and the use of medicinal products inhibiting
prostaglandin synthesis may therefore affect the fertility of women (see section 4.4, 4.6
and 5.3).
5.2 Pharmacokinetic properties
Absorption
Ibuprofen is rapidly absorbed from the gastrointestinal tract. Peak serum concentrations
occur one to two hours after administration.
Distribution
Ibuprofen is rapidly distributed throughout the whole body. The plasma protein binding is
approximately 99%.
Metabolism
Ibuprofen is metabolised in the liver (hydroxylation, carboxylation).
Elimination
The elimination half-life is approximately 2.5 hours in healthy individuals.
Pharmacologically inactive metabolites are mainly excreted (90%) by the kidneys but
also in bile.
5.3 Preclinical safety data
There are no preclinical data considered relevant to clinical safety beyond data included
in other sections of this Summary of product characteristics.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
The core tablet contains:
- Microcrystalline cellulose
- Lactose monohydrate
- Croscarmellose sodium
- Colloidal anhydrous silica
- Polyvinyl povidone
- Maize starch
- Sodium lauril sulfate
- Magnesium stearate
- The tablet coating contains:
- Hydroxypropyl cellulose
- Hypromellose
- Macrogol
- Titanium dioxide
6.2 Incompatibilities
Not applicable
6.3 Shelf life
3 years
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
Opaque PVC/Al blisters packs of 1, 6, 10, 12, 20, 28, 24, 30, 40, 48, 50, 60, 96 and 100
tablets and HDPE container with polypropylene cap containing 12, 20, 28, 24, 30, 40, 48,
50, 60, 96 and 100 tablets
Not all pack sizes may be marketed.
6.6 Special precautions for disposal <and other handling>
No special requirements.
7. MARKETING AUTHORISATION HOLDER
< to be completed nationally>
8. MARKETING AUTHORISATION NUMBER(S)
< to be completed nationally>
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation : 29 April 2014
10. DATE OF REVISION OF THE TEXT
21 September 2016